Clinical trials: Major Depressive Disorder, completed
Depressive Disorder, Major
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive…
- Trial name
- Moonlight-1 (NCT06785012)
- Testing
- JNJ-89495120
- Where
- 44 sites in United States
- Volunteers
- 105 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major, Bipolar Disorder
A Study of Transcranial Direct Current Stimulation (tDCS) to Treat Depression
Depression is a common illness with an approximate lifetime prevalence of 17 %, conferring a large burden of disease in the community, often due to inadequate treatment.
- Trial name
- NCT00763230
- Testing
- Transcranial direct current stimulation
- Where
- Australia
- Volunteers
- 68 people
- Sponsor
- The University of New South Wales
Bipolar Disorder, Major Depressive Disorder
A Study of Pregnant and Postpartum Women With and Without Mood Disorders
This study is looking at genetic, biological, and environmental causes and how all three may work together to cause postpartum mood episodes.
- Conditions
- Bipolar Disorder, Major Depressive Disorder, Postpartum Depression, Postpartum Psychosis
- Trial name
- NCT03615794
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Depression
Neuronavigation Guided iTBS With Personalized Target for Depression
The study will compare the efficacy of intermittent Theta Burst Stimulation (iTBS) with DLPFC-pgACC personalized target for major depressive disorder (MDD) and explore possible brain network mechanisms.
- Trial name
- NCT05577481
- Testing
- iTBS combined with antidepressants
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Xijing Hospital
Major Depressive Disorder
Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder
The primary objective of this study was to compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) after 24 weeks of treatment.
- Trial name
- NCT01148472
- Testing
- Escitalopram, Duloxetine
- Volunteers
- 294 people
- Sponsor
- H. Lundbeck A/S
Recurrent Major Depression
Neural Effects of Wellness Classes in Women With Vulnerability to Depression ("The Women's Wellness Study")
The primary objective of the study is to examine the efficacy of mindfulness based cognitive therapy (MBCT) on the prevention of relapse in women with a history of depression.
- Trial name
- WWS (NCT04106375)
- Testing
- Online mindfulness based cognitive therapy intervention
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Boulder
Depressive Disorder, Major
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-RWE (NCT05841030)
- Testing
- No Intervention
- Where
- 95 sites in United States, Argentina and 9 more
- Volunteers
- 545 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes, Depression
Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians
The primary aim of the study is to compare the effect of three different interventions on lifestyle risk factors and biological risk factors for type 2 diabetes in depressed Cambodians.
- Trial name
- DREAM (NCT02502929)
- Testing
- Social Services, Lifestyle, Lifestyle Plus Medication Therapy Management
- Where
- 3 sites in United States
- Volunteers
- 182 people
- Sponsor
- UConn Health
Major Depressive Episode
Major Depression and Messenger RNAs
Major Depressive Episode (MDE) affects nearly 15% of the general population. In a preliminary study, the investigators identified 12 genes whose expression was either altered between patient and control samples and/or between…
- Trial name
- NCT00998231
- Testing
- blood sample
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Major Depressive Disorder
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).
- Trial name
- NCT04466345
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- University Health Network, Toronto
Major Depressive Disorder
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing…
- Trial name
- NCT01437657
- Testing
- RO4917523 0.5 mg, RO4917523 1.5 mg
- Where
- 76 sites in United States, Chile and 7 more
- Volunteers
- 319 people
- Sponsor
- Hoffmann-La Roche
Major Depression
PUFA Augmentation in Treatment of Major Depression
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder.
- Trial name
- NCT00067301
- Testing
- Polyunsaturated Fatty Acids (PUFA), Citalopram
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Treatment Resistant Depression, Major Depressive Disorder
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
In this proof of concept study, the investigators plan to administer iv ketamine interleaved with ECT days. Patients with treatment resistant depression who are deemed to be eligible for ECT treatment will randomly be assigned to…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT02522377
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Major Depressive Disorder
A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive…
- Trial name
- NCT00073203
- Testing
- R228060
- Where
- United States
- Volunteers
- 488 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Major
Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)
To assess the initial pharmacokinetic profile of single doses of 25mg and 50 mg of DVS SR to healthy subjects.
- Trial name
- NCT00440427
- Testing
- Desvenlafaxine Sustained Release (DVS SR)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depression
Psychotherapeutic Text Messaging for Depression Pilot Study
Major depression is the leading cause of disability in the United States and is a major contributor to suicide, a leading cause of premature death.
- Trial name
- TEXT4U (NCT02872454)
- Testing
- Text Messaging
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Michigan
Major Depressive Disorder, Obsessive-Compulsive Disorder
Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers
The objective of this study is to compare the rate and extent of absorption of paroxetine hydrochloride 20 mg tablets (test) and Paxil® (reference) administered as 20 mg tablet under fed conditions.
- Conditions
- Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Social Anxiety Disorder
- Trial name
- NCT03504475
- Testing
- Paroxetine Hydrochloride Tablet 20 mg, Paxil® 20 mg
- Where
- 2 sites in China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Major Depressive Disorder, Bipolar Disorder
Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders
This study will investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) for mood stabilization in perinatal women (preconception, pregnant, and postpartum) with a history of mood disorders.
- Trial name
- MBCT (NCT02150681)
- Testing
- Mindfulness-based cognitive therapy
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder…
- Trial name
- NCT00635219
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 766 people
- Sponsor
- H. Lundbeck A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.